{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allergic+Conjunctivitis&page=2",
    "query": {
      "condition": "Allergic Conjunctivitis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allergic+Conjunctivitis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T16:41:23.280Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00891436",
      "title": "Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis to Tree Pollen or Grass Pollen"
      ],
      "interventions": [
        {
          "name": "Fluticasone furoate nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2009-04",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2012-12-03",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891436"
    },
    {
      "nct_id": "NCT01390961",
      "title": "Comparison of Tolerability Between Two Allergy Drops",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "alacaftadine and naphazoline HCl & pheniramine maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hom, Milton M., OD, FAAO",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 48,
      "start_date": "2011-08",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2011-07-11",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Azusa, California",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01390961"
    },
    {
      "nct_id": "NCT01751126",
      "title": "Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vernal Keratoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "NOVA22007 ''Ciclosporin''",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen SAS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "4 Years to 18 Years"
      },
      "enrollment_count": 169,
      "start_date": "2013-04-29",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 4,
      "location_summary": "Glendale, California • Irvine, California • Rancho Cordova, California + 1 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01751126"
    },
    {
      "nct_id": "NCT03231969",
      "title": "A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Bilastine 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Bilastine 0.4%",
          "type": "DRUG"
        },
        {
          "name": "Bilastine 0.6%",
          "type": "DRUG"
        },
        {
          "name": "Bilastine 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Faes Farma, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2017-07-20",
      "completion_date": "2017-10-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-16",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03231969"
    },
    {
      "nct_id": "NCT05265910",
      "title": "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "olopatadine hydrochloride ophthalmic solution 0.7%",
          "type": "DRUG"
        },
        {
          "name": "loratadine 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Tears Naturale",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andover Research Eye Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-12-14",
      "completion_date": "2022-04-23",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05265910"
    },
    {
      "nct_id": "NCT01332188",
      "title": "Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "AC-170 0.05%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.1%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.24%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2011-04",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2017-08-30",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01332188"
    },
    {
      "nct_id": "NCT01470118",
      "title": "A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Conjunctivitis, Allergic"
      ],
      "interventions": [
        {
          "name": "alcaftadine 0.25% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "olopatadine 0.2% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2011-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-02-21",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01470118"
    },
    {
      "nct_id": "NCT01860664",
      "title": "Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "hydrocortisone ophthalmic ointment 0.5%",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Koffler Vision Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2013-05",
      "completion_date": "2017-01-01",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860664"
    },
    {
      "nct_id": "NCT03038971",
      "title": "Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Conjunctivitis",
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Dose Level 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Woodmont Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-03-30",
      "completion_date": "2017-04-29",
      "has_results": false,
      "last_update_posted_date": "2018-02-26",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038971"
    },
    {
      "nct_id": "NCT00241319",
      "title": "Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "R89674 (generic name not yet established)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vistakon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2005-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-09-27",
      "last_synced_at": "2026-06-07T16:41:23.280Z",
      "location_count": 5,
      "location_summary": "Indianapolis, Indiana • Lewiston, Maine • Rochester, New York + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lewiston",
          "state": "Maine"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241319"
    }
  ]
}